DelveInsight's "Primary Progressive Multiple Sclerosis (PPMS) Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Primary Progressive Multiple Sclerosis (PPMS) market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The report also covers emerging drugs, current treatment practices, Primary Progressive Multiple Sclerosis (PPMS) market shares of the individual therapies, a detailed current Primary Progressive Multiple Sclerosis (PPMS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the market.
According to the National Multiple Sclerosis Society, primary-rogressive multiple sclerosis (PPMS) is a neurodegenerative disease that interferes with the brain's ability to control the body. There are four main types of MS: relapsing-remitting MS (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS), and progressive-relapsing MS. Each type might be mild, moderate, or severe.
PPMS is characterized by worsening neurologic function (accumulation of disability) from the onset of symptoms, without early relapses or remissions. PPMS can be further characterized at different points in time as either active (with an occasional relapse and/or evidence of new MRI activity) or not active, as well as with progression (evidence of disease worsening on an objective measure of change over time, with or without relapse or new MRI activity) or without progression.
Primary Progressive Multiple Sclerosis (PPMS) Market Key Facts
- As per the estimates provided by Columbia University Medical Center (2018), on average, people with the primary progressive form of MS start having symptoms between ages 35 and 39.
- As per the National Multiple Sclerosis Society, about 15% of the total estimated MS patients in the United States with multiple sclerosis (MS) have the primary progressive form of the disease (PPMS).
- According to a study by Harding et al, (2017), Primary progressive MS commonly comprises between 7.9% and 21.7% of total MS cohorts. Recent studies have estimated the frequency of PPMS in Asia at between 3% and 5.7%.
- According to available literature, no gender bias has been observed in the case of PPMS
- As per a study conducted by the Houzen et al. (2017), titled “Consistent increase in the prevalence and female ratio of multiple sclerosis over 15 years in northern Japan,” out of all MS cases, only 2% of participants with MS were found to be primary progressive and established the relatively lower rates of progressive MS in northern Japan than in western countries.
- According to a study published by Schmidt et al. (2017) titled “Olfactory dysfunction in patients with primary progressive MS”, 84% of participants with PPMS were found to have an impaired sense of smell, compared with just 31% of those with relapsing-remitting MS.
- According to Multiple Sclerosis Trust, about 1 in 8 people diagnosed with MS are diagnosed with primary progressive MS. In more than 8 out of 10 people with primary progressive MS, the first symptom experienced is stiffness and/or weakness in both legs.
Primary Progressive Multiple Sclerosis (PPMS) Market Trends
The primary-progressive Multiple Sclerosis (PPMS) market size is anticipated to increase in the coming years owing to the increasing prevalent population of PPMS patients in the 7MM. The extensive research and development activities of pharmaceutical companies and the launch of upcoming therapies will also boost the market growth.
The Primary Progressive Multiple Sclerosis (PPMS) market analysis sections of the report help to understand the current and forecasted Primary Progressive Multiple Sclerosis (PPMS) market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers. The report gives complete detail of Primary Progressive Multiple Sclerosis (PPMS) Market Size and Shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
The dynamics of the primary-progressive multiple sclerosis (PPMS) market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rise in the awareness of the diseases, incremental healthcare spending across the world, and expected launch of emerging therapies during the forecast period of 2021–2030. Some of the key players at the global level are diligently involved in the therapeutics development in the PPMS market at the global level. Similarly, some of the companies have recently shifted their focus towards this indication which is expected to create a significant influence on the market size during the forecast period.
Companies in the Primary Progressive Multiple Sclerosis (PPMS) Market include Roche, MediciNova, Mapi Pharma, MedDay Pharma, Brainstorm-Cell Therapeutics, and others. Primary Progressive Multiple Sclerosis (PPMS) Therapies covered in the report include MN-166, NurOwn, GA Depot, Fenebrutinib, and many more.
Primary Progressive Multiple Sclerosis (PPMS) Epidemiology Forecast
The Primary Progressive Multiple Sclerosis (PPMS) epidemiology section covers insights about historical and current Primary Progressive Multiple Sclerosis (PPMS) patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan. It helps to recognize the causes of current and forecasted Primary Progressive Multiple Sclerosis (PPMS) Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Primary Progressive Multiple Sclerosis (PPMS) Epidemiology Segmentation
- Prevalent Cases of Multiple Sclerosis
- Diagnosed Cases of Primary-progressive Multiple Sclerosis
- Prevalent Cases of Primary-progressive Multiple Sclerosis
- Treatable Cases of Primary-progressive Multiple Sclerosis
For more details, visit: Primary Progressive Multiple Sclerosis (PPMS) Market Trends